Page last updated: 2024-09-03

mk 0663 and trimethoprim

mk 0663 has been researched along with trimethoprim in 3 studies

Compound Research Comparison

Studies
(mk 0663)
Trials
(mk 0663)
Recent Studies (post-2010)
(mk 0663)
Studies
(trimethoprim)
Trials
(trimethoprim)
Recent Studies (post-2010) (trimethoprim)
5491732656,989845894

Protein Interaction Comparison

ProteinTaxonomymk 0663 (IC50)trimethoprim (IC50)
Chain A, Dihydrofolate reductaseBacillus anthracis77200
Chain A, dihydrofolate reductase (DHFR)Bacillus anthracis77200
Dihydrofolate reductase Mycobacterium avium0.2588
Dihydrofolate reductaseHomo sapiens (human)1.8206
Dihydrofolate reductaseLacticaseibacillus casei0.3493
Dihydrofolate reductase type 1Escherichia coli0.25
Dihydrofolate reductaseNeisseria gonorrhoeae0.45
Thymidylate synthaseHomo sapiens (human)3.405
Dihydrofolate reductaseStaphylococcus aureus0.0875
Thymidylate synthaseEscherichia coli K-123.405
Dihydrofolate reductaseEscherichia coli K-120.6064
Bifunctional dihydrofolate reductase-thymidylate synthasePlasmodium falciparum K10.01
Dihydrofolate reductase type 1 from Tn4003Staphylococcus aureus0.023
Dipeptidyl peptidase 4Rattus norvegicus (Norway rat)2.7
Dihydrofolate reductasePneumocystis carinii0.7061
Dihydrofolate reductaseCandida albicans0.1361
Dipeptidyl peptidase 4Homo sapiens (human)2.7
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)0.45
Metabotropic glutamate receptor 5Rattus norvegicus (Norway rat)2.73
Mu-type opioid receptorCavia porcellus (domestic guinea pig)2.8
Bifunctional dihydrofolate reductase-thymidylate synthaseToxoplasma gondii3.2206
Bifunctional dihydrofolate reductase-thymidylate synthasePlasmodium berghei ANKA0.12
Dihydrofolate reductaseStreptococcus pneumoniae TIGR40.0297
Dihydrofolate reductaseLactococcus lactis subsp. lactis Il14030.45
Dihydrofolate reductase Bacillus anthracis4.77
Dihydrofolate reductaseRattus norvegicus (Norway rat)1.244
Dihydrofolate reductase Pneumocystis jirovecii0.092

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1

Other Studies

3 other study(ies) available for mk 0663 and trimethoprim

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013